AI Article Synopsis
Article Abstract
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been fully characterized for the potential application as a vaccine adjuvant. In this report, we show that DMXAA does act as an adjuvant due to its unique property as a soluble innate immune activator. Using OVA as a model antigen, DMXAA was demonstrated to improve on the antigen specific immune responses and induce a preferential Th2 (Type-2) response. The adjuvant effect was directly dependent on the IRF3-mediated production of type-I-interferon, but not IL-33. DMXAA could also enhance the immunogenicity of influenza split vaccine which led to significant increase in protective responses against live influenza virus challenge in mice compared to split vaccine alone. We propose that DMXAA can be used as an adjuvant that targets a specific innate immune signaling pathway via IRF3 for potential applications including vaccines against influenza which requires a high safety profile.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605442 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060038 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Intravenous immunoglobulin ameliorates doxorubicin-induced intestinal mucositis by inhibiting the Syk/PI3K/Akt axis and ferroptosis.
Apoptosis
December 2024
Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, 610052, Chengdu, China.
Background: Chemotherapy-induced mucositis (CIM) significantly impacts quality of life and reduces survival in patients treated with specific chemotherapeutic agents. However, effective clinical treatments for CIM remain limited. Intravenous immunoglobulin (IVIg), a therapeutic derived from pooled human plasma, is widely used to treat inflammatory diseases.
View Article and Find Full Text PDFTRIM23 promotes 5-Fluorouracil resistance in colorectal cancer by upregulating GALNT4 expression.
Apoptosis
December 2024
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China.
5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents for colorectal cancer (CRC), but its application is often limited by resistance. Tripartite motif containing 23 (TRIM23) has been reported to be dysregulated in various tumors and involved in tumor progression and chemotherapy resistance. However, its relationship with CRC 5-FU resistance and the underlying mechanism are still unclear.
View Article and Find Full Text PDFAMBRA1 drives gastric cancer progression through regulation of tumor plasticity.
Front Immunol
December 2024
State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE) of China, School of Pharmacy, Jinan University, Guangzhou, China.
Background: Stomach adenocarcinoma (STAD) is an aggressive malignancy characterized by high tumor plasticity and heterogeneity. This study investigates the role of Autophagy and Beclin 1 Regulator 1 (AMBRA1) in regulating tumor plasticity in STAD progression.
Methods: Combined with clinical data, the pan-cancer analysis of AMBRA1 was performed to analyze the role of AMBRA1 in STAD.
Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer.
Breast Cancer (Dove Med Press)
December 2024
Department of Surgical Oncology, The Fourth Ward of Breast and Thyroid, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, People's Republic of China.
Aim: The study aimed to culture organoids from tissues of patients with breast cancer (BC) and use the organoids to measure the sensitivity to quercetin and its combination with chemotherapeutic agents.
Methods: Four patient-derived organoids (PDOs) of BC were cultured. The proliferative activity and morphology of PDOs were evaluated on different generations and after resuscitation.
Herbal drug‑based nanotherapy for hepatocellular carcinoma: Quercetin‑contained nanocarrier as a multipurpose therapeutic agent against hepatocellular carcinoma (Review).
Biomed Rep
February 2025
Department of Molecular Biology and Genetics, School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Cancer remains one of the leading causes of morbidity and mortality worldwide, with hepatocellular carcinoma (HCC) accounting for ~75% of all primary liver cancers and exhibiting a high incidence rate. Unfortunately, the response rate to chemotherapeutic agents for liver cancer is relatively low, primarily due to the development of drug resistance and the lack of targeted therapeutic agents. The present study focused on the anticancer mechanisms of quercetin and the development of innovative nanocarriers designed to enhance its efficacy against HCC while mitigating drug resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!